Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASE1 | P07998 | 1/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.60 |
| ▸ | TK2 | O00142 | 3/20 | 0.55 |
| ▸ | TK1 | P04183 | 4/20 | 0.52 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.52 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16349867 | 0.91 | RNASE1 (0.71) | RNASE1SLC6A2TK2TK1ABCG2 | |
| SCHEMBL13901238 | 0.91 | RNASE1 (0.71) | RNASE1SLC6A2TK2TK1ABCG2 | |
| SCHEMBL8999382 | 0.90 | TK2 (0.67) | RNASE1SLC6A2TK2TK1ABCG2 | |
| SCHEMBL27790846 | 0.84 | SLC6A2 (0.64) | RNASE1SLC6A2TK2TK1ABCG2 | |
| SCHEMBL19407973 | 0.84 | RNASE1 (0.71) | RNASE1SLC6A2TK2TK1 | |
| SCHEMBL774263 | 0.84 | RNASE1 (0.68) | RNASE1SLC6A2TK2TK1 | |
| SCHEMBL16287348 | 0.84 | RNASE1 (0.68) | RNASE1SLC6A2TK2TK1 | |
| SCHEMBL14681227 | 0.84 | RNASE1 (0.68) | RNASE1SLC6A2TK2TK1 | |
| SCHEMBL3337696 | 0.84 | RNASE1 (0.71) | RNASE1SLC6A2TK2TK1 | |
| SCHEMBL767324 | 0.84 | RNASE1 (0.68) | RNASE1SLC6A2TK2TK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110039798-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES WITH ANTIVIRAL AND ANTIMICROBIAL PROPERTIES | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039798-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES WITH ANTIVIRAL AND ANTIMICROBIAL PROPERTIES | SAMHD1, TLR3, MAVS | RNASE1 631/4885SLC6A2 2383/4885TK2 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.